Pinned post
I’m incredibly excited to share some big news to ring in the new year: @modella_ai is joining @AstraZeneca!
From the very beginning, Modella was built with a clear conviction: for #AI and #machinelearning to solve grand challenges in #oncology, it has to meaningfully improve how clinicians and scientists work - reducing friction in discovery and enabling better decisions where complexity is highest. That belief shaped our focus in building not only better foundation models, but also breakthrough systems that can reason across the biological spectrum, from single cells to #pathology slides to patient cohorts.
When we first partnered with AstraZeneca, it was immediately clear that we shared this mission. Transforming oncology and biomarker discovery requires more than powerful models. It demands deep clinical context, rigorous validation, and scale. This next step brings those elements together by combining Modella’s #GenAI and #AgenticAI capabilities with AstraZeneca’s oncology portfolio and translational science expertise, unlocking impact that wouldn’t be possible otherwise.
Building Modella alongside this team has been one of the most meaningful experiences of my career thus far. From our earliest angels to our most recent hires, every person has contributed to our mission in immeasurable ways: @AI4Pathology, Jill Stefanelli, Long Phi Le, @MYLu97, Gabi Raia, David Dalton, @kuanchen22, Paul Doucet, @chenbowen118, Drew Williamson! I’m excited to bring this team into AstraZeneca and continue our work with Jorge Reis-Filho and the broader AZ organization.
Please see our press release at: businesswire.com/news/home/2026…
From the very beginning, Modella was built with a clear conviction: for #AI and #machinelearning to solve grand challenges in #oncology, it has to meaningfully improve how clinicians and scientists work - reducing friction in discovery and enabling better decisions where complexity is highest. That belief shaped our focus in building not only better foundation models, but also breakthrough systems that can reason across the biological spectrum, from single cells to #pathology slides to patient cohorts.
When we first partnered with AstraZeneca, it was immediately clear that we shared this mission. Transforming oncology and biomarker discovery requires more than powerful models. It demands deep clinical context, rigorous validation, and scale. This next step brings those elements together by combining Modella’s #GenAI and #AgenticAI capabilities with AstraZeneca’s oncology portfolio and translational science expertise, unlocking impact that wouldn’t be possible otherwise.
Building Modella alongside this team has been one of the most meaningful experiences of my career thus far. From our earliest angels to our most recent hires, every person has contributed to our mission in immeasurable ways: @AI4Pathology, Jill Stefanelli, Long Phi Le, @MYLu97, Gabi Raia, David Dalton, @kuanchen22, Paul Doucet, @chenbowen118, Drew Williamson! I’m excited to bring this team into AstraZeneca and continue our work with Jorge Reis-Filho and the broader AZ organization.
Please see our press release at: businesswire.com/news/home/2026…
www.businesswire.com Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale 
